Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia

Atherosclerosis. 2010 Sep;212(1):40-1. doi: 10.1016/j.atherosclerosis.2010.06.033. Epub 2010 Jun 25.
No abstract available

Publication types

  • Comment

MeSH terms

  • Apolipoprotein B-48 / blood
  • Apolipoprotein C-III / blood
  • Biomarkers / blood
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Cholesterol / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dietary Fats / administration & dosage
  • Dietary Fats / metabolism
  • Exenatide
  • Fatty Acids, Nonesterified / blood
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / prevention & control*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Injections, Subcutaneous
  • Insulin / blood
  • Lipoproteins / blood
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Postprandial Period
  • Receptors, Glucagon / agonists*
  • Time Factors
  • Treatment Outcome
  • Triglycerides / blood
  • Venoms / administration & dosage
  • Venoms / therapeutic use*

Substances

  • Apolipoprotein B-48
  • Apolipoprotein C-III
  • Biomarkers
  • Blood Glucose
  • Dietary Fats
  • Fatty Acids, Nonesterified
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin
  • Lipoproteins
  • Peptides
  • Receptors, Glucagon
  • Triglycerides
  • Venoms
  • remnant-like particle cholesterol
  • Cholesterol
  • Exenatide